| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/27/2006 | CA2592269A1 Pharmaceutical polymer composition for oral controlled-release delivery of terbutaline sulfate |
| 07/27/2006 | CA2591948A1 Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| 07/27/2006 | CA2591702A1 Methods and compositions for treatment of viral infections |
| 07/27/2006 | CA2575547A1 Substituted quinobenzoxazine analogs and methods of using thereof |
| 07/27/2006 | CA2565965A1 Pde4b inhibitors and uses therefor |
| 07/27/2006 | CA2564112A1 Dalbavancin compositions for treatment of bacterial infections |
| 07/27/2006 | CA2562685A1 Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety |
| 07/26/2006 | EP1683863A2 A method for enhancing neurone survival and agents useful for same |
| 07/26/2006 | EP1683811A2 Compositions and methods for the treatment of tumors |
| 07/26/2006 | EP1683809A1 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 07/26/2006 | EP1683807A1 Combination products for use in antitumoral treatment, comprising an antibody capable of inhibiting the activity of CSF-1 |
| 07/26/2006 | EP1683805A1 Novel inhibitor for advanced glycation endproduct formation and aldose reductase inhibitor |
| 07/26/2006 | EP1683803A1 Water soluble prodrugs of hindered alcohols or phenols |
| 07/26/2006 | EP1683799A1 3-Amino-6-aryl(or 6-heteroaryl)-4-R²-thieno[2,3-b]pyridin-2-carboxylic acid amides, pharmaceutical compositions comprising the said and their use as inhibitors of TNFalpha release |
| 07/26/2006 | EP1683798A1 Novel fused polycyclic compound having heterocycle and medicinal use thereof |
| 07/26/2006 | EP1683797A1 Heterocyclic spiro compound |
| 07/26/2006 | EP1683796A1 Pyrazolopyridines, their preparation and their medical use |
| 07/26/2006 | EP1683795A1 Crystalline forms of cis-5-fluoro-N-¬4-(2-hydroxy-4-methylbenzamido)cyclohexyl|-2-(tetrahydrothiopyran-4-yloxy)nicotinamide |
| 07/26/2006 | EP1683794A1 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
| 07/26/2006 | EP1683790A1 3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands |
| 07/26/2006 | EP1683788A1 The derivatives of pyridone and the use of them |
| 07/26/2006 | EP1683786A1 Vitamin d3 lactam derivative |
| 07/26/2006 | EP1683529A1 Inclusion compound of porphyrin metal complex and albumin |
| 07/26/2006 | EP1683527A1 Method of inhibiting secretase activity |
| 07/26/2006 | EP1683526A1 Aqueous solution preparation containing aminoglycoside antibiotic and bromfenac |
| 07/26/2006 | EP1683525A1 Sustained-release phenylalanine derivative preparation for oral administration |
| 07/26/2006 | EP1683524A1 Solid dispersion or medicinal solid dispersion preparation of phenylalanine derivative |
| 07/26/2006 | EP1683523A1 2-Phenylquinoxalines as inhibitors for MPP1 |
| 07/26/2006 | EP1683522A1 Use of benzoxazins in the manufacture of a medicament to prevent or treat acute tolerance to morphinic compounds |
| 07/26/2006 | EP1683521A1 Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same |
| 07/26/2006 | EP1683520A2 Water-soluble paclitaxel produgs |
| 07/26/2006 | EP1683519A1 Preventive/therapeutic agent for speech disorder |
| 07/26/2006 | EP1683518A1 Pharmaceutical formulation of a stable formoterol-containing propylene glycol solution for use in inhalation therapy and method of preparing it |
| 07/26/2006 | EP1683516A2 Stable pharmaceutical formulations of zonisamide and methods for their manufacture |
| 07/26/2006 | EP1683515A2 Bismuth-containing compounds in topical dosage forms |
| 07/26/2006 | EP1683511A1 Squamous-regulating product containing urea and its cosmetologic application |
| 07/26/2006 | EP1682606A2 Anion-binding polymers and uses thereof |
| 07/26/2006 | EP1682574A2 The use of eukaryotic genes affecting chromatin separation for diagnosis and treatment of proliferative diseases |
| 07/26/2006 | EP1682573A2 The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases |
| 07/26/2006 | EP1682565A1 Iap nucleobase oligomers and oligomeric complexes and uses thereof |
| 07/26/2006 | EP1682564A1 METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES |
| 07/26/2006 | EP1682563A1 Bifunctional macrolide heterocyclic compounds and mehtods of making and using the same |
| 07/26/2006 | EP1682562A1 A stabilized azithromycin composition |
| 07/26/2006 | EP1682556A2 Polymorphous forms of rifaximin as antibiotics |
| 07/26/2006 | EP1682555A1 Macrocyclic kinase inhibitors |
| 07/26/2006 | EP1682554A1 Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
| 07/26/2006 | EP1682552A1 Tocopherol-modified therapeutic drug compounds |
| 07/26/2006 | EP1682551A2 Bicyclic pyrazolone cytokine inhibitors |
| 07/26/2006 | EP1682550A1 Substituted naphthyridinone derivatives |
| 07/26/2006 | EP1682548A1 Pyridopyrimidinones |
| 07/26/2006 | EP1682547A1 Rsv polymerase inhibitors |
| 07/26/2006 | EP1682546A1 Peptidomimetic compounds, stereoselective process for their preparation, their use as biologically active synthetic intermediates |
| 07/26/2006 | EP1682545A1 Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation |
| 07/26/2006 | EP1682544A2 Hydroxylamine substituted imidazo ring compounds |
| 07/26/2006 | EP1682543A1 Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same |
| 07/26/2006 | EP1682542A1 Novel crystalline anhydride with anticholinergic effect |
| 07/26/2006 | EP1682541A1 Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same |
| 07/26/2006 | EP1682540A1 Azolidinecarbonitriles and their use as dpp-iv inhibitors |
| 07/26/2006 | EP1682538A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications |
| 07/26/2006 | EP1682537A1 Modulators of cellular adhesion |
| 07/26/2006 | EP1682535A1 Heteroaryl derivatives as ppar activators |
| 07/26/2006 | EP1682534A2 Pyrimidin-4-one compounds, compositions, and methods |
| 07/26/2006 | EP1682532A1 Pyrimidines as inhibitors of phosphoinositide-3-kinases (pi3k) |
| 07/26/2006 | EP1682531A2 Substituted heterocyclic compounds and methods of use |
| 07/26/2006 | EP1682530A1 Substituted pyrrole-indoles as inhibitors of pai-1 |
| 07/26/2006 | EP1682529A2 Methods for synthesizing quinolinone compounds |
| 07/26/2006 | EP1682528A1 BENZO [b][1,4] DIOXEPINE DERIVATIVES |
| 07/26/2006 | EP1682524A1 Novel keto-oxadiazole derivatives as cathepsin inhibitors |
| 07/26/2006 | EP1682523A1 Morpholine derivatives as norepinephrine reuptake inhibitors |
| 07/26/2006 | EP1682521A1 Macrocyclic lactams and pharmaceutical use thereof |
| 07/26/2006 | EP1682520A1 Amide derivatives |
| 07/26/2006 | EP1682519A1 Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors |
| 07/26/2006 | EP1682518A1 Dicationic triaryl analogs as anti-protozoan agents |
| 07/26/2006 | EP1682516A2 Immobilized n-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets |
| 07/26/2006 | EP1682514A1 11- o-methylgeldanamycin compounds |
| 07/26/2006 | EP1682511A2 Methods and compositions for selectin inhibition |
| 07/26/2006 | EP1682510A2 Methods and compositions for selectin inhibition |
| 07/26/2006 | EP1682509A1 Pyridine carboxylic acid derivatives as glucokinase modulators |
| 07/26/2006 | EP1682508A1 Phenyl derivatives as ppar agonists |
| 07/26/2006 | EP1682507A1 Benzannelated compounds as ppar activators |
| 07/26/2006 | EP1682504A2 Hydroxy piperidine derivatives to treat gaucher disease |
| 07/26/2006 | EP1682502A1 Sulfonyltetrahydro-3h-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands |
| 07/26/2006 | EP1682499A1 4-biarylyl-1-phenylazetidin-2-ones |
| 07/26/2006 | EP1682498A1 Novel prostamides for the treatment of glaucoma and related diseases |
| 07/26/2006 | EP1682496A2 Analgesic compounds, their synthesis and pharmaceutical compositions containing them |
| 07/26/2006 | EP1682495A1 Polymorphic form of n- (r)-2,3-dihydroxy-propoxy -3,4-d ifluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
| 07/26/2006 | EP1682486A1 Quaternary amino-functional chalcones |
| 07/26/2006 | EP1682484A1 Omega-substituted-naphthyloxyalklamino derivatives as antihyperglycemic agents and preparation |
| 07/26/2006 | EP1682483A2 Process for the preparation of polymorphs of selective serotonin reuptake inhibitor |
| 07/26/2006 | EP1682211A1 Transdermal drug delivery method and system |
| 07/26/2006 | EP1682205A1 Implantable infusion pump for the administration of intrathecal gabapentin for treatment of pain |
| 07/26/2006 | EP1682185A2 Compositions and methods for treating a posterior segment of an eye |
| 07/26/2006 | EP1682183A2 Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor |
| 07/26/2006 | EP1682182A1 Novel combination containing a stimulator of soluble guanylate cyclase and a lipid-lowering substance |
| 07/26/2006 | EP1682181A2 Combination of a vegf receptor inhibitor with a chemotherapeutic agent |
| 07/26/2006 | EP1682176A1 Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer |
| 07/26/2006 | EP1682172A2 Methods and compositions using adiponectin for treatment of cardiac disorders and for stimulation of angiogenesis |
| 07/26/2006 | EP1682169A1 Compositions and methods of treatment |
| 07/26/2006 | EP1682162A1 Use of prickly pear (opuntia) plant parts and/or extracts for the treatment of depressions |
| 07/26/2006 | EP1682161A1 Polymerizable emulsions for tissue engineering |